REGENSBURG, GERMANY--(MARKET WIRE)--Jul 24, 2008 --
- Having once again doubled the production capacities last year, GENEART plans to increase its capacities fivefold by the end of 2010 - The GENEART AG business operations live up to expectations in 2008 confirming the positive prognoses

Regensburg, July 24, 2008 - Today, all points on the agenda presented at GENEART AG's Annual Shareholder's Meeting have been approved by a large majority of the shareholders. The Board of Directors' strategy to achieve a sustainable and profitable growth of GENEART AG, the world's leading provider of synthetic genes and specialist in the field of Synthetic Biology, has also been endorsed by their shareholders. In 2007, the GENEART Group achieved an annual net profit of EUR 1,177,939.39 (IFRS). As approved by today's Shareholders' Meeting resolution, the net profit of GENEART AG of EUR 2,113,190.21 (HGB, German Commercial Code) is carried forward.

In his address to the shareholders and later in the general debate, the management expressed satisfaction with the business development now and in recent months. Christian Ehl, CEO and CFO of the GENEART AG comments: "We expect a continued strong growth in 2008 and affirm our prognoses of achieving sales of EUR 16.5M.to 18.0M and an operating result (EBIT) between EUR 2.5M to 2.8M. Our growth strategy is in full force. We have just doubled our capacities in the course of a year and are planning to increase them again by 100 % in 2009. Our plan is to boost our capacities by as much as fivefold by the end of 2010. As another objective in 2009, we pursue a listing change at the Frankfurt Stock Exchange from the Entry Standard to the Prime Standard segment to make the GENEART AG shares even more attractive to International investors."

Professor Ralf Wagner, CEO and CSO of the GENEART AG, adds: "By acquiring additional large scale orders and setting up strategic partnerships we have again expanded our leadership role in the biotechnology and pharmaceutical markets." As an example, the US National Cancer Institute (NCI, part of the US American National Institutes of Health NIH) has already extended the 2008 follow-up order by US$ 0.8M. This increased this year's NIH order of genes synthesized by GENEART for the NIH Mammalian Gene Collection to a total of US$ 2.7M. Our technology and distribution collaboration with Boehringer Ingelheim, a leading global provider of plasmid DNA, is based on the transfer of technologies for the production and purification of plasmid DNA. The strategic partnership with QIAGEN serves the distribution of standardized mammalian genes and ideally complements the GENEART core business of synthesizing gene sequences according to customer specifications.

In the 1st Quarter of 2008, the GENEART AG net sales increased by 61% to EUR 3.9M (Q1 2007: EUR 2.4M). In the same period, the operating result (EBIT) were EUR 0.5M (Q1 2007: EUR 0.4M). The 2008 half year report and 2nd Quarter financial statement for the GENEART AG will be published on August 13, 2008.

For further inquiries, please contact:

Bernd Merkl GENEART AG Josef-Engert-Str. 11 93053 Regensburg Germany Phone: +49-(0)941-942 76-638 Fax: +49-(0)941-942 76-711 ir@geneart.com www.geneart.com

Frank Ostermair Better Orange IR & HV AG Haidelweg 48 81241 Munich Germany Phone: +49-(0)89-8896906-10 Fax: +49-(0)89-8896906-66 info@better-orange.de www.better-orange.de

Legal Information This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.

About GENEART AG In 2000, GENEART entered the gene synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the Synthetic Biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. Our production and service spectrum spans a wide range, from the production of synthetic genes according to DIN EN ISO 9001:2000, to the creation of gene libraries in the combinatorial biology, to the development and production of DNA-based biologically active substances. The GENEART AG in Regensburg (Germany) and the subsidiary GENEART Inc. in Toronto (Canada) employ more than 190 people. Since May 2006, GENEART is listed on the German Stock Exchange.

Copyright © Hugin AS 2008. All rights reserved.